Trending...
- Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion
- R&B Artist Mike Davis Announces Debut Full-Length Album Full Circle, Releasing April 7
- Ocean County College Introduces Pathways to Simplify the Student Journey and Strengthen Career Connections
SAN JOSE, Calif. - PennZone -- CPC Scientific Inc., a leading global peptide CRDMO (Contract Research, Development, and Manufacturing Organization) has invested in a new peptide API (Active Pharmaceutical Ingredient) manufacturing site, bringing many new jobs to Rocklin, California. The 41,000 sq ft facility located at 3880 Atherton Rd, Rocklin, CA 95765 will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity and will diversify CPC Scientific's supply chain.
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on The PennZone
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on The PennZone
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on The PennZone
- Accelerating into Active Oil Production with over 100 Barrels per day now being produced as Dual-revenue engine begins Generating Cash Flow: $IBG
- Finland emerges as clear Eurovision 2026 favourite – analysis of 12 bookmakers by Vedonlyöntisivut
- Mac Mountain Selects netElastic vRouter for LightCraft Broadband-as-a-Service Platform
- 88% Revenue Growth; Charging Into the Future with Explosive Growth, Strategic EV Expansion and Infrastructure Dominance Signal a Breakout Opportunity
- Forge Resources Unlocks Major Gold-Copper System in Yukon as Drilling Success and Strategic Assets Fuel High-Impact Growth Story for: $FRGGF
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on The PennZone
- Game Day Private Jets Launches REVUP Platform to Transform Fan & Donor Travel Into a Revenue Engine for College Athletics
- Heritage at South Brunswick Team Celebrates Major Wins at NJBA Sales and Marketing Awards
- Girl Scouts of Eastern Pennsylvania's "Summer of Sisterhood" Offers Two Lehigh Valley-based Camps
- Girl Scouts of Eastern Pennsylvania's "Summer of Sisterhood" Returns to Camp Valley Forge
- Best Companies Group Launches Best Places to Work in Maine Program
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
Source: CPC Scientific Inc.
0 Comments
Latest on The PennZone
- Primo Sewer Cleaning Acquires Industry-Leading Hydro Jetter Mongoose Jetter Model 123
- UK Financial Ltd Confirms CATEX Exchange Integration of SMPRA and LTNS 1 Ahead of Compliance-Based Trading Activation
- Best Companies Group Opens Free Registration for Best Credit Unions to Work For Program
- Ashikaga Flower Park's "Great Wisteria Festival 2026"
- Washington County PA Real Estate is Changing Here's What Homeowners Need to Know Before Selling
- Architect of Neurodiversity Will Lead the First U.S. Team of Autistic Children to the "Genius Cup" in Hiroshima, Japan, in 2027
- Deborah E. Jones Introduces Emotional Sovereignty, a Powerful New Book on Emotional Mastery, Resilience, and Intentional Living
- New Research Identifies "The Busy Effect": 89% of Americans Want a Laid-Back Vacation — Only 15% Actually Achieve It
- Alchemy 43 Appoints Shane Smith as CEO to Drive Operational Performance and Scalable Growth
- Best Spiritual Healing, Meditation & Retreats in Sedona — Rise Meditation Helps You Find and Book Transformational Experiences
- $16 Billion Market by 2034 in Underwater Drones Presents Huge Opportunity for AI-Powered Autonomous Vehicle Serving Defense & Commercial Customers
- Appliance EMT Named Among Jacksonville's Top 3 Appliance Repair Companies by ThreeBestRated®
- The Scratch-Off Dead Zone - is your state lottery failing?
- Geekstorians Nominated For Best History Podcast In The 30th Annual Webby Awards
- Quality Water Treatment Unveils SoftPro Elite HE Water Softener for City Water, Setting a New Standard in Residential Water Treatment
- UK Financial Ltd Chooses PUMP.FUN App to Launch Maya Meme's Minor-League Meme Coins and Announces Lifetime Airdrop Program
- Boston Industrial Solutions Expands Its Industry-Leading UV Ink Portfolio with the Launch of a Matte Ink - Natron® UVPZ
- The Eichelberger Performing Arts Center Announces 6 Youth Summer Camps
- Feldman Shepherd's Ezra Wohlgelernter Honored by SeniorLAW Center for Two Decades of Service
- Century Fasteners Corp. Exhibiting at 2026 MRO Americas Show – April 21-23, 2026 – Booth #2257
